Drug Search Results
More Filters [+]

IAMA-6

Alternative Names: IAMA-6, IAMA6
Latest Update: 2024-03-08
Latest Update Note: Clinical Trial Update

Product Description

IAMA-6 is an early-stage compound that has shown encouraging in vitro and in vivo proof of concept results in idiopathic and secondary forms of autism. The compound is designed to directly target and inhibit NKCC1, a sodium-potassium chloride co-transporter responsible for maintaining chloride homeostasis in neurons. By improving chloride homeostasis, IAMA-6 inhibits neuronal hyperexcitability commonly associated with autism and other neurological disorders. Pre-clinical mechanistic studies have also demonstrated that IAMA-6 was well tolerated and did not induce diuresis. IAMA-6 has the potential to be developed for multiple autism spectrum disorders and other CNS indications including neurodevelopmental and neurodegenerative diseases. (Sourced from: https://iamatherapeutics.com/science/)

Mechanisms of Action: NKCC Inhibitor

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IAMA Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IAMA-6

Countries in Clinic: Italy

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Epilepsy

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ECS_IAMA23_0101

P1

Recruiting

Epilepsy

2024-09-01

Recent News Events